SCHEDULE: BVF Partners Reduces Stake in Kymera Therapeutics

BVF Partners and affiliated entities sold 1,630,658 shares of Kymera Therapeutics at $106.50 per share on June 26, 2026.

Summary

• BVF Partners and its affiliates (the Reporting Persons) reduced their beneficial ownership in Kymera Therapeutics, Inc. through the sale of 1,630,658 shares.
• The shares were sold at a price of $106.50 per share on June 26, 2026.
• Following the transaction, the Reporting Persons maintain an aggregate beneficial ownership of 5,237,151 shares, representing approximately 6.3% of the issuer's outstanding common stock.
• The filing also discloses a new stock option grant of 6,068 shares to board member Gorjan Hrustanovic, with economic benefits assigned to the Partners entity.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-negative event, as the significant sale of shares by a major institutional holder often signals a reduction in conviction or profit-taking.

Positives

• The sale of shares at $106.50 indicates significant liquidity and market interest in the issuer's stock at that price point.
• The Reporting Persons maintain a substantial remaining stake of 6.3%, signaling continued, albeit reduced, investment interest.

Negatives

• The divestment of over 1.6 million shares by a major institutional investor may be perceived as a lack of confidence in near-term upside.
• The reduction in ownership stake could exert downward pressure on the share price due to increased supply.

Risks

• Future sales by the Reporting Persons could further impact the market price of the common stock.
• The exercise of Pre-Funded Warrants is subject to a 9.99% ownership blocker and potential HSR Act notification thresholds, which may limit liquidity for the holders.
• The economic interest agreement regarding board member stock options creates a complex relationship between the director and the investment firm.

Future Outlook

The filing does not provide specific forward-looking guidance for the company, focusing instead on the reporting of beneficial ownership changes and contractual arrangements regarding director compensation.

Management Comments

• The Reporting Persons certify that the information set forth in the statement is true, complete, and correct.

Industry Context

StockSavvy.ai notes that institutional divestment in the biotech sector is common following significant share price appreciation, often representing portfolio rebalancing rather than a fundamental shift in the issuer's clinical prospects.

Comparison to Industry Standards

• The 6.3% remaining stake held by BVF Partners remains a significant institutional position, consistent with typical long-term biotech investment strategies.
• The use of Pre-Funded Warrants with a 9.99% blocker is a standard mechanism in biotech financing to manage regulatory compliance and ownership thresholds.

Corporate Governance

Related Party Transactions

• Gorjan Hrustanovic is obligated to transfer the economic benefit of shares acquired through specific stock options to Partners.

Stakeholder Impact

• Shareholders may experience increased volatility due to the large volume of shares sold.
• The alignment of director economic interests with the investment firm may influence board decision-making.

Next Steps

• Vesting of stock options granted to Gorjan Hrustanovic on June 24, 2027, or upon the next annual meeting.

Key Dates

Recommendation

While the sale is significant, the remaining 6.3% stake suggests the firm maintains a long-term interest. Investors should monitor for further selling pressure before adjusting positions.

Keywords

Kymera Therapeutics, BVF Partners, Schedule 13D, Biotechnology, Insider Selling, Equity Divestment